Penumbra PEN Thrombectomy — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Penumbra in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Penumbra's thrombectomy — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Penumbra's thrombectomy — revenue?
- Penumbra (PEN) reported thrombectomy — revenue of $253.92M in Q1 2026.
- How has Penumbra's thrombectomy — revenue changed year-over-year?
- Penumbra's thrombectomy — revenue increased by 12.1% year-over-year, from $226.54M to $253.92M.
- What is the long-term trend for Penumbra's thrombectomy — revenue?
- Over 4 years (2021 to 2025), Penumbra's thrombectomy — revenue has grown at a 21.3% compound annual growth rate (CAGR), from $437.78M to $947.92M.
- What does thrombectomy — revenue mean?
- The total sales revenue generated from the company's thrombectomy medical device product line.
- How do you interpret thrombectomy — revenue?
- An increase indicates growing market share, successful product adoption, or increased procedure volumes in the thrombectomy space, while a decrease may signal competitive pressure or market saturation.
- How does thrombectomy — revenue compare across companies?
- Comparable to specialized medical device revenue segments in companies focused on interventional cardiology, neurovascular, or vascular surgery markets.